Astec LifeSciences Limited (NSE:ASTEC)
India · Delayed Price · Currency is INR 650.50
+23.50 (3.75%)
Jul 31, 2026, 3:29 PM IST
Astec LifeSciences Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Operating Revenue | 4,382 | 4,457 | 3,781 | 4,577 | 6,282 | 6,766 |
Other Revenue | 26.51 | 24.31 | 31.57 | 9.41 | 3.31 | 3.34 |
| 4,408 | 4,481 | 3,813 | 4,586 | 6,285 | 6,769 | |
Revenue Growth | 9.39% | 17.53% | -16.86% | -27.03% | -7.15% | 21.16% |
Cost of Revenue | 2,870 | 3,083 | 3,056 | 3,249 | 4,069 | 3,920 |
Gross Profit | 1,538 | 1,399 | 757.2 | 1,338 | 2,216 | 2,849 |
Selling, General & Admin | 647.46 | 639.31 | 621.68 | 629 | 533.27 | 513.32 |
Other Operating Expenses | 829.91 | 803.79 | 797.59 | 762.03 | 911.8 | 788.77 |
Operating Expenses | 1,922 | 1,892 | 1,856 | 1,754 | 1,782 | 1,646 |
Operating Income | -384.15 | -493.82 | -1,099 | -415.94 | 434.56 | 1,203 |
Interest Expense | -307.68 | -340.8 | -362.76 | -248.56 | -201.58 | -86.95 |
Interest & Investment Income | 5.21 | 5.21 | 8.03 | 1.51 | 40.49 | 2.63 |
Currency Exchange Gain (Loss) | 11.92 | 11.92 | 15.9 | 49.71 | 83.92 | 72.45 |
Other Non Operating Income (Expenses) | 13.53 | 13.53 | 1.74 | -3.09 | -3.85 | -0.35 |
EBT Excluding Unusual Items | -661.18 | -803.97 | -1,436 | -616.37 | 353.54 | 1,191 |
Gain (Loss) on Sale of Assets | -0.66 | -0.66 | 20.18 | -1.11 | -5.24 | 0.14 |
Other Unusual Items | -20.94 | -20.94 | - | - | - | - |
Pretax Income | -667.21 | -810 | -1,410 | -617.48 | 349.47 | 1,211 |
Income Tax Expense | -1.64 | -1.24 | -62.78 | -148.57 | 93.53 | 312.43 |
Earnings From Continuing Operations | -665.57 | -808.76 | -1,347 | -468.91 | 255.94 | 898.83 |
Minority Interest in Earnings | -0.41 | -0.41 | -0.41 | -0.39 | -0.29 | -0.24 |
Net Income | -665.97 | -809.18 | -1,348 | -469.3 | 255.65 | 898.59 |
Net Income to Common | -665.97 | -809.18 | -1,348 | -469.3 | 255.65 | 898.59 |
Net Income Growth | - | - | - | - | -71.55% | 38.14% |
Shares Outstanding (Basic) | 22 | 21 | 20 | 20 | 20 | 20 |
Shares Outstanding (Diluted) | 22 | 21 | 20 | 20 | 20 | 20 |
Shares Change | 12.61% | 9.18% | 0.01% | 0.02% | 0.04% | 0.05% |
EPS (Basic) | -30.16 | -37.79 | -68.71 | -23.93 | 13.04 | 45.87 |
EPS (Diluted) | -30.16 | -37.79 | -68.71 | -23.93 | 13.04 | 45.85 |
EPS Growth | - | - | - | - | -71.56% | 38.06% |
Free Cash Flow | - | -862.44 | -302.21 | -1,253 | -426.03 | -803.74 |
Free Cash Flow Per Share | - | -40.28 | -15.41 | -63.88 | -21.73 | -41.01 |
Dividend Per Share | - | - | - | 1.500 | 1.500 | 1.500 |
Dividend Growth | - | - | - | 0% | 0% | 0% |
Gross Margin | 34.89% | 31.21% | 19.86% | 29.17% | 35.26% | 42.09% |
Operating Margin | -8.71% | -11.02% | -28.83% | -9.07% | 6.91% | 17.78% |
Profit Margin | -15.11% | -18.06% | -35.34% | -10.23% | 4.07% | 13.28% |
Free Cash Flow Margin | - | -19.25% | -7.93% | -27.32% | -6.78% | -11.87% |
EBITDA | 59.84 | -52.8 | -670.07 | -61.53 | 759.35 | 1,536 |
EBITDA Margin | 1.36% | -1.18% | -17.57% | -1.34% | 12.08% | 22.70% |
D&A For EBITDA | 443.98 | 441.02 | 429.14 | 354.41 | 324.79 | 332.88 |
EBIT | -384.15 | -493.82 | -1,099 | -415.94 | 434.56 | 1,203 |
EBIT Margin | -8.71% | -11.02% | -28.83% | -9.07% | 6.91% | 17.78% |
Effective Tax Rate | - | - | - | - | 26.76% | 25.79% |
Revenue as Reported | 4,459 | 4,532 | 3,869 | 4,638 | 6,412 | 6,870 |